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L-DOPA-induced dyskinesia (LID) represents one of the major problems of the long-term
therapy of patients with Parkinson’s disease (PD). Although, the pathophysiologic
mechanisms underlying LID are not completely understood, activation of the extracellular
signal regulated kinase (ERK) is recognized to play a key role. ERK is phosphorylated
by mitogen-activated protein kinase kinase (MEK), and thus MEK inhibitor can prevent
ERK activation. Here the effect of the MEK inhibitor PD98059 on LID and the
associated molecular changes were examined. Rats with unilateral 6-OHDA lesions of
the nigrostriatal pathway received daily L-DOPA treatment for 3 weeks, and abnormal
involuntary movements (AIMs) were assessed every other day. PD98059 was injected in
the lateral ventricle daily for 12 days starting from day 10 of L-DOPA treatment. Striatal
molecular markers of LID were analyzed together with gene regulation using microarray.
The administration of PD98059 significantly reduced AIMs. In addition, ERK activation
and other associated molecular changes including 1FosB were reversed in rats treated
with the MEK inhibitor. PD98059 induced significant up-regulation of 418 transcripts
and down-regulation of 378 transcripts in the striatum. Tyrosine hydroxylase (Th) and
aryl hydrocarbon receptor nuclear translocator (Arnt) genes were down-regulated in
lesioned animals and up-regulated in L-DOPA-treated animals. Analysis of protein levels
showed that PD98059 reduced the striatal TH. These results support the association of
p-ERK1/2,1FosB, p-H3 to the regulation of TH and ARNT in themechanisms of LID, and
pinpoint other gene regulatory changes, thus providing clues for identifying new targets
for LID therapy.
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INTRODUCTION
L-DOPA-induced dyskinesia (LID) that are associated with chronic dopamine replacement therapy
still represent one of the major problems in the management of patients with Parkinson’s disease.
Accumulating evidence manifests that overly sensitized dopamine D1 receptor transmission and
its downstream signaling pathway play a key role in the mechanisms of LID (Gerfen et al., 2002;
Westin et al., 2007; Darmopil et al., 2009; Feyder et al., 2011). Several postsynaptic signaling
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molecules are involved in this pathway, including phospho-
Thr34-DARPP-32 (p-DARPP32), phosphorylated extracellular
signal-regulated kinase 1/2 (p-ERK1/2), 1FosB, and phospho-
Ser10-histone H3 (p-H3) (Hakansson et al., 2004; Pavon et al.,
2006; Santini et al., 2007; Cao et al., 2010; Du et al., 2015; Potts
et al., 2015). In animal models of PD, striatal overactivation
of these neurochemicals characterizes the molecular profile of
the supersensitive response underlying dyskinetic behaviors.
P-ERK1/2 and dopamine D1 receptor, are implicated in various
forms of synaptic plasticity, particularly in late long-term
potentiation (LTP) and thereby in cocaine addiction, learning
and memory (Kelleher et al., 2004a,b; Granado et al., 2008;
Borkar et al., 2013; Cahill et al., 2014; Suarez et al., 2014).
The dopamine D1 receptor signaling pathway is associated with
overactivation of ERK1/2 in rodent models of LID (Westin
et al., 2007; Darmopil et al., 2009; Feyder et al., 2011). The
phosphorylation level of ERK1/2 can be increased by D1 agonists
(and decreased by D1 antagonists) in the striatum of rats with 6-
hydroxydopamine (6-OHDA) lesions (Gerfen et al., 2002; Santini
et al., 2009a) and even in intact animals (Gangarossa et al.,
2013). ERK1/2 was also found to be the downstream signaling
of the cAMP/PKA/DARPP-32 pathway in animal models of LID,
although studies have been inconsistent (Santini et al., 2007;
Dupre, 2008; Gerfen et al., 2008; Lebel et al., 2010). In addition,
ERK1/2 appears to activate the mammalian target of rapamycin
complex 1 (mTORC1) (Roux et al., 2007; Carriere et al., 2008)
that is a critical regulator of mRNA translation especially in
relation to long-lasting synaptic plasticity and memory (Costa-
Mattioli et al., 2009). Persistent activation of mTORC1 mediated
by ERK1/2-D1 receptor stimulation has been found in the
striatum of amouse LIDmodel (Santini et al., 2009b). Rapamycin
and CCI-779, the inhibitor of mTOR, modify mTORC1 targets
and can reduce abnormal involuntary movements (AIMs) in
rodents (Santini et al., 2009b; Decressac and Björklund, 2013).
Other established molecular hallmark of LID is 1FosB, a
truncated isoform of FosB, that is a chronic transcription factor.
1FosB possesses unique stability properties compared with all
other Fos family members (Andersson et al., 1999, 2003; Cenci,
2002; Cao et al., 2010). Chronic L-DOPA treatment induces
FosB/1FosB accumulation in the striatum that may result not
only in dyskinesia but also an insensitive response to L-DOPA
(Engeln et al., 2016). Furthermore, alternative inactivation of
FosB-1FosB-expressing neurons in the striatum attenuates LID
(Doo et al., 2014; Engeln et al., 2016). Another important marker
is p-H3 whose posttranslational modification is induced by
L-DOPA (Santini et al., 2007, 2009a). P-H3 is co-expressed with
dynorphin in striatal neurons, and thus, its changes may associate
with the transcriptional alterations underlying LID (Darmopil
et al., 2009).
We aimed at reducing the phosphorylation of ERK1/2 to
examine its role in the regulation of other biomarkers of
LID and associated transcriptional changes. We used the MEK
inhibitor PD98059 and whole transcriptome analysis using
microarray analysis in rats with unilateral 6-OHDA lesions
and chronic exposure to L-DOPA treatment. In line with
previous work (Santini et al., 2007), PD98059 prevented the
phosphorylation of ERK1/2 and histone H3, and reduced the
abnormal accumulation of 1FosB. Also, the inhibitor showed a
powerful effect of counteracting AIMs. Importantly, numerous
genes were regulated in association with AIMs. We focused on
the function of the following genes, tyrosine hydroxylase (Th)
and aryl hydrocarbon receptor nuclear translocator (Arnt), which
regulates Th (Teh et al., 2007). The administration of PD98059
neutralized the L-DOPA-induced changes in Arnt and Th levels.
These results provide evidence for a significant interplay between
LID biomarkers (p-ERK1/2, 1FosB, p-H3) and the regulation
of striatal Th and Arnt genes in the pathophysiology of LID
development. The analysis of the transcriptomemay also provide
clues for identifying further genes that are involved in LID
mechanisms.
MATERIALS AND METHODS
Animals
Adult, male Sprague–Dawley rats (Beijing HFK Bioscience Co.,
Ltd., China) weighing 230–250 g (7 weeks old) were housed with
free access to food and water, 12 h light/dark cycle, constant
temperature and humidity. Animal use and care were conformed
to the Guidelines of Laboratory Animals Ethics of Tongji Medical
College, Huazhong University of Science and Technology. The
protocol was approved by the Ethics Committee of Huazhong
University of Science and Technology.
Drugs
6-OHDA (2 µg/µl) and apomorphine hydrochloride (0.1 µg/µl)
were dissolved in saline with 0.02% ascorbic acid, and L-DOPA
methyl ester and benserazide (12 and 6 mg/kg) were dissolved
in saline immediately before use (Sigma-Aldrich). PD98059
(Calbiochem) was dissolved in 20% DMSO, 10% Tween80, and
diluted to 0.4 µg/µl with saline (Miller and Marshall, 2005).
Both isoflurane and pentobarbital were purchased from Sigma-
Aldrich.
6-OHDA Lesion and Cannula Implantation
Rats were deeply anesthetized with isoflurane (induction 3%,
maintenance 1.5%) in oxygen and mounted on the stereotaxic
frame. A temperature controller system was used to maintain
body temperature at 37◦C. 6-OHDA (2 µg/µl, 4 µl) was
injected into the right medial forebrain bundle through a 10-µl
microsyringe at a rate of 0.5 µl/min at the following stereotactic
coordinates: relative to bregma,−4.4 mm anterior (A),+1.5 mm
lateral (R), and 7.8 mm deepness (D) (Lindgren et al., 2009). In
33 rats, a guide cannula connected to a microinjection system
(RWD Life Science Co., Ltd) was implanted to the right lateral
ventricle (A −0.7 mm, R +1.5 mm, D 4.0 mm) according to
atlas of Paxinos and Watson (2005) and secured to the skull
with dental cement. The efficacy of the dopaminergic lesion
was tested by measuring contralateral turning behavior with an
acute subthreshold dose of apomorphine (0.05 mg/kg s.c.) 2
weeks post-surgery. Only rats exhibiting more than 200 turns
contralateral to the lesion side in 30 min were considered to be
compatible with the model of full lesion, and were chosen for
further study (Boldry et al., 1995). TH staining revealed also a
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complete lesion of substantia nigra (SN) ipsilateral to the lesion
(see Figure 1).
Drugs Treatment and Behavioral
Assessment
Three days after apomorphine screening (Figure 2A), 45
successful hemiparkinsonian rats received intraperitoneal
injections of L-DOPA plus benserazide (12/6 mg/kg) once daily.
L-DOPA-induced AIMs were recorded every other day. Rats
were observed for 1 min every 35 min intervals for a total of 140
min following L-DOPA treatment. AIMs were evaluated using
the validated AIMs scale. Orofacial, limb, and axial dyskinesia
were graded from score 0 to 4: 0 = absent; 1 = occasional,
present during less than half min; 2 = frequent, present during
more than half min; 3 = continuous but interrupted by strong
sensory distraction; 4 = continuous, not interrupted by strong
sensory distraction (Winkler et al., 2002; Lundblad et al., 2004).
The total of axial, limb and orofacial dyskinesia was also named
ALO dyskinesia and the maximum ALO dyskinesia score in each
session was 48. Rotation (contralateral turns) test was performed
as before (Breger et al., 2013) at day 1, 4, 12, 16, and 20, and only
turns of completed 360◦ were counted.
From day 10, 42 rats with complete dyskinesia (ALO AIMs
score = 12 at 70 min after L-DOPA) were divided into 3 groups:
LID group, LID + PD98059 group, and LID + vehicle group.
There was cannula implantation for each rat in the latter two
groups. A volume of 3µl PD98059 solution (0.4µg/µl) or vehicle
was infused into the right lateral ventricle over 6 min through
the cannula connected to the microinjection system half hour
before L-DOPA administration from day 10 to 21 (Figure 2A).
The infusion needle was left in place for 2 min at the end of
infusion for drug diffusion. Normal rats with sham operation
and hemiparkinsonian rats were chosen as normal group and PD
group, respectively. There were 14 rats in each group.
The stepping test was carried out 15 min before (pre-) and
after (post-) L-DOPA treatment as previously described (Pinna
et al., 2007, 2010) on days 2, 10, and 18. Rats were moved on
the surface of the table for 0.7m in 4 s by the experimenter.
The number of adjusting steps of left and right forelimbs in the
forward directions was counted.
All behavioral tests were performed by a blinded examiner.
Tissue Preparation
At day 21, 4 h after the last L-DOPA treatment, 4 rats of
each group (normal, PD, LID, LID + Vehicle, and LID +
PD98059) were anesthetized with an overdose of pentobarbital
and then perfused transcardially with saline followed by 4% ice-
cold paraformaldehyde (PFA) in phosphate buffer (pH 7.4). Brain
tissues were removed, post-fixed with 4% PFA overnight and
25% sucrose for 24 h. Then the fixed samples were embedded
in paraffin for immunohistochemistry and immunofluorescence.
Another 10 rats of each group were sacrificed by decapitation.
Brain tissues were rapidly removed, dissected for striatum
on powdered dry ice. Striatum from 4 of the 10 rats were
immediately stored at −80◦C until protein extraction for
Western blotting analysis, and 6 of the 10 were incubated in
RNAlater (Qiagen) at 4◦C overnight and then stored at −80◦C
for further Microarray analysis (3 rats) and real-time quantitative
PCR (3 rats).
FIGURE 1 | Tyrosine hydroxylase (TH) immunostaining in substantia nigra (SN) in the rat 6-OHDA lesion model. (A,B,D) Analysis of differences in TH
positive cell counts in SN of the intact and lesioned side. ***p < 0.001 (t-test, N = 4/group). Scale bar is 100 µm. Error bars represent SEM. (C) Integral field-vision of
the SN with TH immunostaining. The boxes indicate the SN in which positive neurons are counted (an area of 0.2 mm2 ).
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FIGURE 2 | Experimental design and behavior changes induced by different treatment. (A) Timeline of experiments Studies began with cannula placement
into the lateral ventricle and 6-OHDA lesions of MFB followed by apomorphine test identifying rats with complete lesions. The bottom arrow shows the timeline for all
groups of chronic treatment with L-DOPA methyl ester (12 mg/Kg) plus benserazide (6 mg/Kg) once daily. Behavioral assessment was done every other day. The
upper arrow shows the daily lateral ventricle infusion with vehicle or PD98059 half hour before L-DOPA injection. All animals were sacrificed on day 21 for further
studies (N = 14/group). (B–E) Effect of PD98059 on AIMs in 6-OHDA-lesioned rats (B). ALO (total of axial, limb, and orofacial) AIMs scores that were obtained every
35 min over 140 min following the L-DOPA injection every other day. (C,D) Total ALO AIMs scores within 140 min sessions following drug administration on day 10 (C)
and 20 (D). (E) Contralateral turns that were counted on days 1, 4, 8, 12, 16, and 20. (F,G) Stepping tests scores 15 min before (pre-) and after (post-) L-DOPA
administration on day 2, 10, and 18. *p < 0.05, **p < 0.01 in (B–E), LID + PD98059 vs. LID + Vehicle, *p < 0.05 in (F,G), post-L-DOPA vs. pre-L-DOPA
administration (one-way ANOVAs followed by Tukey HSD and LSD post-hoc test). Error bars represent SEM.
Western Blotting
Brain tissues were homogenized with glass homogenizers in ice-
cold enhanced RIPA lysis buffer, containing 50mMTris (pH 7.4),
150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1%
SDS, 5 mM EDTA, 2 mM Na3VO4, 1 mM PMSF, 10 mM NaF,
and a complete set of protease inhibitors (Roche, USA). Lysates
were centrifuged at 12,000 g at 4◦C for 15 min and the protein
concentrations were determined by a BCA assay kit (Pierce,
Rockford). The resulting supernatant was added with 1% SDS
loading buffer, and boiled for 10 min. Equal amounts of protein
(some 40 µg) of each sample were separated on 10% SDS–
polyacrylamide gel electrophoresis (SDS-PAGE), transferred
for 90 min onto polyvinylidene fluoride (PVDF) membranes
(Millipore, USA), blocked for 1 h at 25◦C in 5% non-fat powdered
milk dissolved in Tris-buffered saline containing 0.1% Tween
20 (TBST), and immunoblotted overnight at 4◦C with primary
antibodies. The following primary antibodies were deployed:
rabbit polyclonal antibody anti-1FosB (1:500; Cell Signaling
Technology; #9890), rabbit monoclonal antibody against p44/42
MAPK (ERK1/2; 1:1,000; Cell Signaling Technology; #4695),
rabbit monoclonal antibody against phospho-p44/42 MAPK (p-
ERK1/2; Thr202/Tyr204; 1:1,000; Cell Signaling Technology;
#4370). The membranes were washed in TBST, incubated with
horseradish peroxidase-conjugated goat anti-rabbit secondary
antibody (1:5,000; GeneTex: GTX213110-01), and visualized
with an ECL detection kit (Thermo Scientific). The membranes
were stripped and incubated with rabbit polyclonal antibody
against β-actin (1:1,000; AntGene; ANT010) as a loading control.
Bands intensities were analyzed quantitatively by Gel Pro
Analyzer version 6.0 (Media Cybernetics, Bethesda, MD, USA).
Densitometry was represented as relative optical density. All
Western blots were repeated not less than three times.
Immunohistochemistry and
Immunofluorescence
The paraffin-embedded brain tissues were sectioned at thickness
of 4 µm. SN and striatum sections were mounted on
glass slides, deparaffinized by xylene for 15 min (2 times),
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dehydrated in graded ethanol solutions, baked in the basic
antigen retrieval buffer (pH = 6.0), and washed with phosphate
buffer (pH 7.4) for 5 min (3 times). After washing, sections
were blocked with 3% Bovine Serum Albumin for 30 min at
room temperature (RT), then incubated with diluted primary
antibody in a humidified chamber overnight at 4◦C overnight.
The following primary antibodies were used: rabbit polyclonal
antibody against FosB (1:100, sc-48, Santa Cruz, detecting FosB-
1FosB) for the immunohistochemistry staining in striatum,
rabbit polyclonal antibody against TH (1:750, ab112, Abcam)
for the immunohistochemistry staining in SN. Then all sections
were washed with phosphate buffer (pH 7.4) for 5 min (3 times),
subsequently incubated with biotinylated goat anti-rabbit IgG
at 37◦C for 50 min, washed again as above, incubated with
Horseradish peroxidase labeled streptavidin fluid at 37◦C for
30 min, washed, followed by DAB solutions for 5 min, washed,
counterstained with Harris hematoxylin for 3 min, dehydrated in
graded ethanol solutions, and eventually cover slipped. Images
were collected through an Olympus camera connected to the
microscope at the same light intensity, and analyzed using Image-
Pro Plus software by an independent experimenter blinded to the
sections by counting the number of positive cells in the SN or
dorsal striatum of the lesioned side (relative to bregma, A −4.5
mm for SN and A 0.6 mm for striatum sections, N = 4 sections
for counting). TH staining in SN was used to estimate the extent
of the dopaminergic lesion (shown in Figure 1).
Immunofluorescence staining shared a same procedure with
immunohistochemistry staining before secondary antibodies
incubation. Primary antibodies used in the double staining
contained rabbit polyclonal antibody against FosB-1FosB
(1:100, sc-48, Santa Cruz, detecting FosB-1FosB) and mouse
monoclonal against p-H3 (1:200, Ab14955, Abcam). Primary
antibodies used in the single staining contained mouse
monoclonal antibody against HIF-1β (1:200, ab2771, Abcam,
detecting ARNT) and rabbit polyclonal antibody against TH
(1:750, ab112, Abcam). After being washed, sections were
incubated in dark with an appropriately diluted Alexa 488- or
Cyanine 3-coupled secondary antibodies for 50 min followed
by DAPI (4′, 6-diamidino-2-phenylindole) dyeing nucleus for
10 min. Images were collected using laser confocal microscopy
marked with image manipulation software, and analyzed using
Image-Pro Plus software by an independent experimenter
blinded to the sections by counting the number of positive cells
in the dorsal striatum of the lesioned side (relative to bregma, A
0.6 mm for striatum sections, N = 4 sections for counting).
Microarray
Samples (striatum of lesioned side) were sent to Shanghai
biotechnology Corporation for whole transcriptome analysis
using microarray. Total mRNA was extracted using TRIZOL
Reagent (Cat#15596-018, Life technologies, Carlsbad, CA, US)
according to the manufacturer’s instructions. RNA integrity
was evaluated with the Agilent Bioanalyzer 2,100 and RNA
6,000 Nano/Pico Kit (Agilent Technologies, Santa Clara, CA,
US). Qualified total RNA was further purified by RNeasy
micro kit (Cat#74004, QIAGEN, GmBH, Germany) and RNase-
Free DNase Set (Cat#79254, QIAGEN, GmBH, Germany).
Concentrations of extracted RNA were assessed with the
Nanodrop spectrophotometer (Nanodrop Technologies). A total
of 100–150 ng RNA per sample was reverse transcribed to
double stranded cDNA and then transcribed into cRNA using
the Genechip WT Expression Kit (Affymetrix). Second cycle
was carried out following generation of cRNA in order to
transform the cRNA into single-strand cDNA. The cDNA
was fragmented and the Genechip WT Terminal Labeling Kit
(Affymetrix) was used to label the single-stranded DNA with
biotin. Samples were hybridized to an Affymetrix Genechip Rat
Gene 2.0 ST Array Platform. Array hybridization and wash was
performed using GeneChip R© Hybridization, Wash and Stain Kit
(Cat#900720, Affymetrix, Santa Clara, CA, US) in Hybridization
Oven 645 (Cat#00-0331-220V, Affymetrix, Santa Clara, CA, US),
and Fluidics Station 450 (Cat#00-0079, Affymetrix, Santa Clara,
CA, US) according to the manufacturer’s instructions. Slides
were scanned by GeneChip R© Scanner 3000 (Cat#00-00212,
Affymetrix, Santa Clara, CA, US).
Real-Time Quantitative PCR
Total mRNA was extracted and reversely transcribed using the
same method as in microarray. Quantification of mRNAs was
performed by real-time PCR using Agilent-Stratagene Mx3000P
Q-PCR System. The following primers (Invitrogen) were used:
Th forward, 5′-GACATTGGACTTGCATCTCTG-3′, and Th
reverse, 5′-GCTGGTAGGTTTGATCTTGGT-3′; Arnt forward,
5′-GAACCGAGAATGGCTGTGGATG-3′, and Arnt reverse, 5′
-GCTGTGACCTCTGGATTGTGTTAG-3′; FosB forward, 5′-G
TGAGAGATTTGCCAGGGTC-3′, and FosB reverse, 5′-GTGA
GAGATTTGCCAGGGTC-3′; beta-actin forward, 5′-GGAGAT
TACTGCCCTGGCTCCTA-3′, and beta-actin reverse, 5′-GACT
CATCGTACTCCTGCTTGCTG-3′. The SYBR Green Premix Ex
TaqTM GC (Takara, RR420A) was employed. The PCR started
with 94◦C for 5 min, and then continued with 40 cycles of 10 s
at 94◦C, 20 s at 60◦C, and 15 s at 72◦C followed by 1 cycle of
30 s at 94◦C, 30 s at 55◦C, and 30 s at 94◦C. Amplification plots
and dissociation curves were obtained to analyze PCRs product
and confirm amplification specificity. Expression levels of mRNA
were determined using the 11CT method. Each sample was
tested in triplicate.
Data Analysis
The Expression Console software (Affymetrix, Santa Clara,
CA, US) was used to format the raw microarray data. Data
pre-processing, including background adjustment, log fold
transformation and normalization was completed using the
“exon level” option in the software. Moreover, the dataset
was normalized using the Robust Multi Array Average (RMA)
method to control the inter-array variability. Normalized signal
intensities of probes which belong to one transcript of each
sample were processed by median for further data analysis. Gene
chip and RNA quality were assessed by examining total mRNA
expression for each striatum. We have submitted the microarray
data to the GEO repository. The GEO accession numbers is
GSE93695.
R software was used to screen the differential gene expression
transcripts (DETs) among these samples. The adjusted P <
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0.05 and fold change (FC) ≥ 1.2 or ≤ 0.8333 were used as
the cut-off criteria. After getting the DETs, we proceeded with
the functional analysis, searching the function and signaling
pathway of the genes. In this step, we used the known databases
mainly, including DAVID Gene Ontology (http://david.abcc.
ncifcrf.gov/). Considering the large amount and complex branch
structure of Gene ontology (GO) biological processes, we used a
significance threshold P < 0.05 for biological process terms.
The co-expression analysis starts by constructing a matrix
of pairwise correlations between all pairs of transcripts across
samples of LID + PD98059, LID + Vehicle and LID group.
We built an unsigned co-expression network with all the 37,177
transcripts in microarray using the Weighted Gene Correlational
Network Analysis (WGCNA) package [PMID: 19114008]. GO
term enrichment tests were performed for individual gene co-
expression modules compared to a background set of all genes
expressed in these brain samples using the R packages GOstats
(version 2.26.0), biomaRt version (2.14.0), AnnotationDbi
(version 1.20.7), and org.Hs.eg.db (version 2.8.0).
To specialize LID + PD98059 from other treatment,
unsupervised hierarchical clustering of the candidates in every
trait module was performed by bootstrapping analysis usingMeV
software (http://www.tm4.org/). Bootstrapping analysis provides
confidence values for the stability of each cluster derived by
hierarchical clustering.
RT-qPCR data were expressed as fold changes in relative gene
expression compared with the Normal group using beta-actin
levels as an endogenous control. The significance level was set
at p< 0.05. Data are presented as mean± SEM.
Statistics
Data were analyzed using one-way analysis of variance (ANOVA)
followed by Tukey HSD or LSD post-hoc tests for multiple
comparisons between groups, and Student’s t-test for comparing
TH positive neurons in the intact and lesioned side of SN. All
statistical analyses were performed in SPSS 21.0 software. The
significance level was set at p< 0.05. Data are presented as mean
± SEM for behavioral assessments, immunohistochemical count,
and blot quantifications.
RESULTS
MEK Inhibitor Attenuated LID
TH immunostaining was used to determine the DA neurons
loss in SN following 6-OHDA lesions (Figure 1). DA neurons
significantly decreased in the lesioned side (t = 23.432, p
< 0.001 Figure 1D). Chronic L-DOPA administration (12
mg/kg, s.c., once daily for 21 days, Figure 2A) to rats with
unilateral nigrostriatal 6-OHDA lesion led to the development
of increasingly severe AIMs (axial, orofacial, limb AIMs) and
rotation, all reaching a plateau after day 9 (Figure 2B, LID and
LID+Vehicle groups). MEK inhibitor PD98059 (1.2µg, injected
into the right lateral ventricle 30 min before L-DOPA on days
10–21) clearly attenuated L-DOPA-induced AIMs after day 13
(Figure 2B). The total ALO (axial, limb and orofacial) scores of
each group (LID, LID + Vehicle, LID + PD98059) were 34.40 ±
0.90, 34.30 ± 0.90, 19.80 ± 1.33 on day 17 [Figure 2B, F(2, 39)
= 62.247, p < 0.01], respectively. ALO scores at day 20 were
decreased by PD98059 at all time points (35, 70, and 105 min
after L-DOPA; Figures 2C,D). In contrast, rotation (contralateral
turns) showed little difference among groups (Figure 2E).
The Stepping test showed that L-DOPA could significantly
improve motor function of the contralateral forelimb in rats with
unilateral nigrostriatal 6-OHDA-lesion (Figures 2F,G). PD98059
did not affect the stepping test scores (Figures 2F,G).
Effects of MEK Inhibitor on the Striatal
Expression of p-ERK1/2, FosB-1FosB, and
p-H3
L-DOPA administration induced a significant increase in
p-ERK1/2 level in the striatum of unilaterally 6-OHDA-
lesioned rats (Figures 3A,B, Supplementary Figure 1). And
this effect was prevented by the inhibitor of MEK PD98059
[Figures 3A,B, Supplementary Figure 1; p-ERK1/2 vs. ERK1/2,
F(4, 15) = 6.244 one-way ANOVA followed by Tukey HSD
and LSD post-hoc test, N = 4/group]. The increase of
p-ERK1/2 was accompanied by overexpression of 1FosB
that represents a net increase of 1FosB (Figures 3A,C,
Supplementary Figure 1). PD98059 also decreased1FosB levels
[Figures 3A,C, Supplementary Figure 1; 1FosB vs. β-actin,
F(4, 15) = 15.543 one-way ANOVA followed by Tukey HSD and
LSD post-hoc test,N = 4/group]. Furthermore, PD98059 reduced
FosB-1FosB immunoreactive neurons in the dorsolateral
striatum on the lesioned side [Figures 3D,E; F(4, 15) = 989.202,
one-way ANOVA followed by Tukey HSD post-hoc test, N =
4/group]. The number of FosB-1FosB immunoreactive neurons
of LID + Vehicle and LID + PD98059 groups was 176.5 ±
4.3/section and 90.3 ± 2.9/section, respectively (Figures 3D,E).
No difference was found between LID + Vehicle and LID
groups. Double immunolabeling images of the two molecules
exhibited colocalization between FosB-1FosB and p-H3 in
rats with dyskinesia (Figure 4A). PD98059 reduced the striatal
co-expression of FosB-1FosB and p-H3 positive cell count
[Figure 4B; co-expression of FosB-1FosB and p-H3, F(3, 12) =
154.413, one-way ANOVA followed by Tukey HSD and LSD
post-hoc test, N = 4/group]. The quantification of neurons with
colocalization in LID + Vehicle group and LID + PD98059
group was 49.25± 2.136, 21.75± 1.493, respectively (Figure 4B).
Quantification demonstrated that about 50 and 25% of striatal
p-H3 positive neurons co-expressed with FosB-1FosB in LID
+ Vehicle group and LID + PD98059 group, respectively
(Figure 4C). P-H3 negative neurons didn’t express FosB-1FosB
(data not shown).
MEK Inhibitor Neutralized Changes in
Gene Expression Associated with LID
Genes Associated with LID and Regulated by MEK
Inhibitor
Gene expression was compared between the lesioned striatum
of rats without L-DOPA treatment (PD group) and that of rats
with AIMs after repeated administrations of L-DOPA for 21
days (LID group; ALO AIMs score = 12 at 70 min after L-
DOPA). Compared with PD group, LID group exhibits 606 up-
regulated transcripts and 932 down-regulated transcripts (p <
0.05 and fold change ≥ 1.2 or ≤ 0.8333; Figure 5A). These
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FIGURE 3 | PD98059 regulates the expression of p-ERK1/2 and FosB-1FosB in the striatum. (A) Levels of ERK1/2, p-ERK1/2, and 1FosB were relatively
quantified in the DA-denervated striatum from each group of rats by Western blotting. (B,C) Analysis of differences in p-ERK1/2 vs. ERK1/2 and 1FosB vs. β-actin in
the lesioned striatum from each group. *p < 0.05, **p < 0.01 (one-way ANOVA followed by Tukey HSD and LSD post-hoc test, N = 4/group). Error bars represent
SEM. (D) Immunohistochemical images of FosB-1FosB in dorsal striatum on the lesioned side from rats of each group (Normal, PD, LID, LID + Vehicle, LID +
PD98059). Scale bar is 100 µm. (E) Analysis of differences in FosB-1FosB positive cells counts in each group. **p < 0.01 (one-way ANOVA followed by Tukey HSD
and LSD post-hoc test, N = 4/group). Error bars represent SEM.
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FIGURE 4 | PD98059 reduces p-H3 and FosB-1FosB positively
immunoreactive cell counts. (A) Double immunolabeling images show
co-localization between p-H3 and FosB-1FosB in the dorsal striatum from
each rat group (PD, LID, LID + Vehicle, LID + PD98059). Scale bar is 50 µm.
(B) Analysis of colocalization of FosB-1FosB and p-H3 positive in each group
(in an area of 0.05 mm2 ). **p < 0.01 (one-way ANOVA followed by Tukey HSD
and LSD post-hoc test, N = 4/group). (C) Percentage of FosB-1FosB and
p-H3 positive cell count in each group (N = 4/group). Error bars
represent SEM.
changes in gene expression are caused by L-DOPA treatment
and are mainly related to the following functions, response to
endogenous stimulus, enzyme linked receptor protein signaling
pathway and several others described in Figure 5B (see also
Supplementary Table 2 for details).
In comparison with LID + Vehicle group, LID+PD98059
group exhibits 418 up-regulated transcripts and 378 down-
regulated transcripts (P < 0.05 and fold change ≥ 1.2 or
≤ 0.8333; Figure 5A). Thus, PD98059 treatment caused large
changes in gene expression mainly related to the following
functions, negative regulation of multicellular organismal
process and several others described in Figure 5B (see also
Supplementary Table 4 for details).
Changes in gene regulation between PD and Normal groups
and between LID + Vehicle and LID groups were also detected
(see Figure 5 and details in Supplementary Tables 1, 3).
The results obtained from comparison of groups were
further analyzed to identify the genes that were regulated
by repetitive L-DOPA, and then changed by PD98059. The
analysis showed 13 genes that were up-regulated by L-
DOPA and down-regulated by PD98059: Ubash3b, Sik1, Hspa4,
Prg4, Agpat9, Tpbg, Hcrtr1, Plaur, Th, Arnt, RGD1564887,
Tshz3, Far1 (Figures 6A,B). Additionally, 17 genes were down-
regulated by L-DOPA and then up-regulated by PD98059: Srpk3,
LOC100362690, Hook2, Zfp316, Runx1, Mir3550, LOC365559,
Ica1l, Map2k6, RGD1562533, Fgfr2, Muc19, Ephb2, Kif6, Cadm2,
and two unnamed transcripts (Figures 6A,B).
Changes in Th, Arnt, and FosB gene expression detected
with microarray analysis were verified with quantitative RT-PCR
(Figures 6C–E). Similar to microarray results, Th and Arnt were
up-regulated by L-DOPA and normalized by PD98059 (P< 0.05).
Only one of the four probes detecting FosB gene (Probe Set ID:
17630237) presented a trend in line with expectations shown in
the quantitative RT-PCR result (Figure 6E), namely up-regulated
by L-DOPA and down-regulated by PD98059. The gene symbol
is set as LOC100360880 in the data, and probe details are shown
in the Supplementary Table 5.
Identification of PD98059-Specific Coexpression
Modules
To further identify a hierarchical network view of co-expressed
genes across LID+PD98059 group, LID + Vehicle group and
LID group subtypes, we applied WGCNA to a dataset containing
3 specimens in each group. All candidates (including protein
coding genes and lncRNA) in this dataset were hierarchically
clustered under unsupervised average linkage and classified
into 45 modules (Figures 7A,B) labeled by color. Each module
was comprised of mutually exclusive co-expressed candidates.
Candidates with no distinct module assignment were grouped in
a gray module by WGCNA. Two of these modules, containing
steelblue and red, were identified using any pre-assigned
phenotype (GS P < 0.05, Figure 7C). The module membership
(MM) vs. gene significance (GS) plots for these modules
(Figure 7C) showed that MM and GS are highly correlated,
indicating that the candidates most significantly associated
with the trait are often also the most important (central)
elements of the respective module. Following the unsupervised
module generation, individual candidate correlations to a specific
treatment were quantified by GS. The average GS of all candidates
within each module is summarized in Figure 7D. This analysis
unveiled positive or negative correlation of certain modules with
PD98059 treatment. The steelblue module contained candidates
negatively correlated to the PD98059 treatment (Figure 7D).
To validate the robustness of the co-expression network as a
specific classifier, it was first applied by unsupervised hierarchical
clustering bootstrap analysis to the expression value of each
sample in a test dataset from which steelblue module were
derived, making it a “PD98059-treatment module,” including
protein metabolic process and RNA modification terms with
GO enrichment analysis (Figure 7E). Similarly, the red module
contained candidates positively correlated to the PD98059
treatment (Figure 7D). And the genes in red module were
involved in protein deacetylation and ubiquitin-dependent
SMAD protein catabolic process (Figure 7E).
Identification and Validation of Hub Networks of
Coexpressed Genes Closely Related to PD98059 and
LID
Four genes in the steelblue module, namely LOC365559, Runx1,
Far1, and Hspa4, and 9 genes in the red module, namely Cadm2,
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FIGURE 5 | Microarray analysis. (A) Gene expression changes induced by each treatment comparing PD vs. Normal, LID vs. PD, LID + Vehicle vs. LID, LID +
PD98059 vs. LID + Vehicle (N = 3/group; p < 0.05, Fold change ≥1.2 or ≤ 0.8333). (B) Gene Ontology analysis about the altered genes from the same group
comparisons.
Kif6, Ephb2, Map2k6, Zfp316, Hook2, Tshz3, RGD1564887, and
Th, were also common specific DETs between LID+ PD98059 vs.
LID + Vehicle and LID vs. PD (red and blue font, respectively;
Figure 6B). This overlap suggests that the genes are crucially
regulated by PD98059 treatment and LID. We further analyzed
these genes in hub networks of co-expressed genes across
transcriptome platforms. There were more than 60 DETs in the
steelblue module closely related with Hspa4 (Figure 8A). There
were also many DETs in the hub network of the red module
related with Map2k6, Hook2, Zfp316, Kif6, and Th (Figure 8B).
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FIGURE 6 | Genes altered by L-DOPA treatment and responsive to PD98059 treatment. (A) The number of common genes in opposite trends between LID vs.
PD and LID + PD98059 vs. LID + Vehicle (p < 0.05, Fold change ≥1.2 or ≤ 0.8333). (B) The common genes from the comparison presented in (A). The red and
green colors in the heatmap represent up-regulation and down-regulation, respectively. The genes marked with red and blue font in the list represent common genes
with red and steel blue module in this figure, respectively. (C–E) Changes in Th, Arnt, and FosB gene expression as detected by quantitative RT-PCR *p < 0.05, **p <
0.01 (one-way ANOVA followed by Tukey HSD and LSD post-hoc test, N = 3/group).
The regulation of these genes may thus be related to LID
development.
Effects of MEK Inhibitor on the Striatal
Expression of TH and ARNT
The expression of TH and ARNT was also analyzed
using Immunofluorescence (Figure 8). Chronic L-DOPA
administration increased the number of TH and ARNT positive
neurons in the striatum of 6-OHDA-lesioned rats (Figure 9).
This effect was reversed by the inhibitor of MEK PD98059
[Figure 9; TH, F(3, 12) = 34.268; HIF-1 β (ARNT), F(3, 12) =
28.696; one-way ANOVA followed by Tukey HSD and LSD
post-hoc test, N = 4/group]. No difference was found between
LID+ Vehicle and LID groups.
DISCUSSION
In this study, we showed that lateral ventricle administration
of PD98059, a selective MEK inhibitor, could reduce LID in
6-OHDA-lesioned rats. Axial, limb, and orofacial AIMs scores
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FIGURE 7 | PD98059-specific co-expression modules across LID+PD98059 group, LID + Vehicle group, and LID groups. (A,B) All candidates (including
protein coding genes and lncRNA) in the dataset (37,177 transcripts in microarray) were hierarchically clustered under unsupervised average linkage and classified into
45 modules labeled by color. (C) The module membership (MM) vs. gene significance (GS) plots for steelblue and red module showed that MM and GS are highly
correlated (GS P < 0.05). (D) The steelblue and red module contained candidates negatively and positively correlated to the PD98059 treatment, respectively. (E) GO
enrichment analysis about transcripts in steel blue and red module (P < 0.05).
Frontiers in Neuroscience | www.frontiersin.org 11 March 2017 | Volume 11 | Article 112
Chen et al. MEK Inhibitor, LID, and Neurochemical
FIGURE 8 | Hub networks of co-expressed genes closely related to PD98059 and LID. (A) Hub network of genes correlative with LOC365559, Runx1, Far1,
and Hspa4 in the steelblue module. (B) Hub network of genes correlative with Cadm2, Kif6, Ephb2, Map2k6, Zfp316, Hook2, Tshz3, RGD1564887, and Th in the red
module.
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FIGURE 9 | PD98059 reduces TH and ARNT (HIF-1 β) immunoreactive cells. (A,C) Examples of immunofluorescent images showing TH and ARNT positive
neurons in the dorsolateral striatum. (B,D) Analysis of differences in TH and ARNT positive cell counts in each group (an area of 0.05 mm2). **p < 0.01 (one-way
ANOVA followed by Tukey HSD and LSD post-hoc test, N = 4/group). Scale bar is 50 µm. Error bars represent SEM.
were significantly decreased since the fourth day of PD98059
administration. In addition, rotational behavior had little changes
with the addition of the inhibitor indicating that this agent did
not neutralize the antiparkinsonian effect of L-DOPA. These
findings are in line with previous results showing that SL327,
other MEK inhibitor, could significantly reduce LID in 6-OHDA-
lesioned mice (Santini et al., 2007) and definitely confirm the key
role of ERK1/2 in the development of rodent LID. As classical
inhibitors of MEK, PD98059 was widely used in a variety of
experiments. It was proved to be highly effective in preventing
the phosphorylation of ERK1/2 that could disrupt drug-paired
contextual cue memories (Miller and Marshall, 2005). In this
study, the increased striatal phosphorylation of ERK1/2 in
hemiparkinsonian rats chronically exposed to L-DOPA could
also be largely reversed by PD98059.
One of the most significant results of this study is that
the antagonistic effect of PD98059 on LID and p-ERK1/2 was
accompanied by other specific molecular changes, particularly
the reduction of 1FosB expression. We have confirmed for the
first time that inhibiting the over-activation of ERK1/2 could
decrease the accumulation of1FosB protein in the striatum. The
FosB gene is ranked in the first place among 28 genes blocked by
SL327, other MEK inhibitor with antidyskinetic effects in mice,
which is consistent with the present results showing that MEK
inhibitor could reduce the transcription of FosB (Charbonnier-
Beaupel et al., 2015). However, we found in the microarray
results that probes for detecting the FosB gene (mRNAAccession:
NM_001256509) were probably not perfectly designed, although
Affymetrix Genechip Rat Gene 2.0 ST was one of the most
advanced whole transcriptome gene chip when we started the
study. Only one of the four probes (Probe Set ID: 17630237)
presented a trend in line with expectations, namely up-regulated
by L-DOPA and down-regulated by PD98059. The gene symbol is
set as LOC100360880 in the data and the probe details are shown
in the Supplementary Table 5. Furthermore, we carried out real-
time quantitative PCR to detect the FosB levels in samples. The
change pattern among groups confirmed the result of Probe
17630237.
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The transcription factor 1FosB is a recognized hallmark of
LID (Andersson et al., 1999; Tekumalla et al., 2001; Cenci,
2002; Cao et al., 2010). Striatal overexpression of 1FosB could
result in abnormal neuronal electrical properties leading not only
to dyskinesia but also to an insensitive response to L-DOPA
that can be responsive to selective blockade of the expression
of this transcription factor (Engeln et al., 2016). The kinetic
profile of 1FosB likely explains the delayed antidyskinetic effect
of PD98059 to the fourth day of treatment. This transcription
factor possesses unique stability properties compared with all
other Fos family members (McClung et al., 2004; Alibhai et al.,
2007; Nestler, 2008, 2015), and this is owned to two contributing
mechanisms. First, 1FosB lacks two critical degron domains,
which are associated with ubiquitination and degradation in the
C-terminus of full-length FosB and all other Fos family proteins.
Second, 1FosB is modified by some protein kinases at the N-
terminus, adding further stability to the protein (Ulery et al.,
2006; Gajewski et al., 2009; Ulery-Reynolds et al., 2009; Cates
et al., 2014). Therefore, 1FosB proteins tend to accumulate in
neurons, and could persist for several weeks after withdrawal of
relevant drug exposure. In this study, AIMs were significantly
reduced starting several days after initiating MEK inhibitor
treatment, and the1FosB level was significantly decreased at the
end of the experiment. Further studies are necessary to explore
the role of certain kinases that mediate 1FosB catabolism and
the contribution of ERK1/2 in the process.
Our microarray data showed that changes in the expression of
a considerable number of genes occur with LID development and
can be changed by MEK inhibition. Compared with the normal
state, there were a total of 961 transcripts changed as a result
of dopaminergic lesion. The regulated genes are related directly
to synaptic transmission, nerve impulse conduction, behavior
and other functions implying that dopamine depletion causes
extensive transcriptional alterations. Furthermore, changes in
1,538 transcripts were involved in the development of LID
after chronic L-DOPA treatment, and changes in 796 transcripts
were associated with PD98059 treatment. The genes regulated
with LID and PD98059 widely participate in transmembrane
receptor protein tyrosine kinase signaling pathway, synaptic
transmission, synaptic plasticity regulation, Ras protein signal
transduction regulation, and other relevant functions. Notably,
L-DOPA and PD98059 could affect some of the same GO
biological processes. The preliminary analysis of GO biological
processes, including enzyme linked receptor protein signaling
pathway, synaptic transmission, cell-cell signaling, and learning
and memory support that these genes, especiallyHspa4, Map2k6,
Hook2, Zfp316, Th, and likely other genes in the hub networks
play important roles in the pathophysiology of LID. We focused
on the most significant changes in gene expression occurred
with PD98059 treatment. According to the in-depth analysis
of the data, we found 13 genes that are up-regulated by L-
DOPA and could be neutralized by PD98059, and 17 genes that
are down-regulated by L-DOPA and could be normalized by
PD98059.
It is important to note that among the 13 genes up-regulated
by L-DOPA and neutralized by PD98059, one was the abnormal
Th expression. Several studies have previously demonstrated that
striatal Th-positive neurons are correlated with severity of LID
and 1FosB expression in hemiparkinsonian mice (Darmopil
et al., 2008; Charbonnier-Beaupel et al., 2015; Keber et al., 2015).
Studies have shown that striatal Th neurons may cooperate with
serotonergic terminals synthesizing dopamine and producing
supraphysiological synaptic DA concentrations, a mechanism
thought to contribute to LID (Keber et al., 2015). However, it was
also reported that the striatal Th-positive neurons co-expressed
with dynorphin and enkephalin, suggesting that they are
medium spiny neurons of the direct and indirect striatal output
pathways (Darmopil et al., 2008). Clearly, Th colocalization with
dynorphin is coherent with our data and the relation to LID
because there is sufficient evidence in support of the direct
pathway role in LID mechanisms. Instead, Th colocalization
with enkephalin is at odds with the specific association of Th
expression with LID mechanisms. It is important to consider
that the function of newly developed Th expression in striatal
neurons inmodels of PD is still under poorly understood, and it is
possible that Th expression serves different functions including a
compensatory mechanism to enhance dopamine actions in both
striatal pathways. On the other hand, the use of D1 or D2 receptor
knock-out mice demonstrated that D1R, but not the D2R is
necessary for L-DOPA-induced expression of striatal Th-positive
neurons (Espadas et al., 2012). Although, transgenic models of
dopamine receptor KO may undergo different gene regulations
with L-DOPA treatment, and here we used wild type animals, the
present data also support the link of striatal Th expression to LID.
In our study, PD98059 significantly neutralized the abnormal Th
expression, which suggests a connection between Th and MEK,
and possibly p-ERK1/2. Of interest, p-ERK1/2 could indirectly
influence Th expression through regulation of the orphan nuclear
receptor Nur-related factor 1(NURR1) because putative ERK1/2
phosphorylation sites were found proximal to theN-terminal AF-
1 region of NURR1, and NURR1 directly induces transcription of
Th gene in midbrain dopamine neurons of the substantia nigra
(Jacobsen et al., 2008). However, we have not found a distinct
change in the Nurr1 gene with microarray among the studied
groups of rats. Therefore, further work is needed to determine
whether the connected regulation of p-ERK1/2-NURR1-Th plays
a mechanistic role in LID.
Another regulated gene in relation to LID and PD98059
was Arnt, whose official full name is aryl hydrocarbon receptor
nuclear translocator. ARNT protein is required for activity
of the Ah (dioxin) receptor and the ligand-binding subunit
to translocate from the cytosol to the nucleus after ligand
binding. Then, the complex initiates transcription of genes.
Its heterodimer with HIF1A acts as a transcriptional regulator
in response to hypoxia (Mannello et al., 2011; Dela Cruz
et al., 2014). It was revealed that ARNT, in concert with
neuronal PAS domain protein 1 (NPAS1), negatively modulates
the expression of Th and that this regulation occurs with
NPAS1 directly binding on the Th promoter (Teh et al., 2007).
However, this is conflicting with our data showing that Arnt gene
expression correlates with Th expression changes associated with
L-DOPA and PD98059 treatment, upregulation and suppression,
respectively. Alternatively, Th expression may be induced by
other transcription factors, for instance NURR1, and Arnt
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regulation could result from adaptive changes to counteract high
Th expression.
Ubash3b and Sik1 genes were regulated in parallel to Th and
Arnt in this study. The official full name of Ubash3b is ubiquitin
associated and SH3 domain containing B. This gene encodes a
protein that promotes accumulation of activated target receptors
on the cell surface, exhibits tyrosine phosphatase activity, and
down-regulates proteins that are dually modified by both protein
tyrosine phosphorylation and ubiquitination. One possibility
would be that UBASH3B contribute to the accumulation of
1FosB due to UBASH3B mediated accumulation of activated
target receptors. The official full name of Sik1 is salt-inducible
kinase 1. Sik1 is one of the CREB-target genes. SIK1 induction
is thought to act as a negative feedback signal preventing
persistent CREB/TORC1-dependent transcription in situations
of long-lasting neuronal activity (Hu et al., 2015). It has
been shown that Sik1 plays a key role in cocaine addiction
(Dietrich et al., 2012), which also shares a mechanism associated
with 1FosB upregulation. Map2k6 and Ephb2 are among
the 17 genes down-regulated by L-DOPA and up-regulated
by PD98059. The official full name of Map2k6 is mitogen-
activated protein kinase kinase 6. MAP2K6 is the activator
of p38 MAPK and is involved in synaptic plasticity including
cue-induced relapse to heroin seeking, learning and memory
(Bolshakov et al., 2000; Fanous et al., 2013). The official full
name of Ephb2 is Eph receptor B2. EphB2 is a member
of the EphB family of receptor tyrosine kinases, and could
increase synaptic NR1 and NR2B expression, prevent down-
regulation of dephosphorylated p38 MAPK and phosphorylated
CREB in Aβ1-42 oligomer-treated neurons (Geng et al., 2013).
EphB2 is considered a neuroprotective factor for hippocampal
neurons with a potential therapeutic role in Alzheimer’s disease
(Miyamoto et al., 2016). LID is thought to share similar
plasticity changes with drug addiction and memory/learning
processes. The present study showed that the Ubash3b, Sik1,
Map2k6, and Ephb2, all associated with mechanisms of synaptic
plasticity, are regulated by L-DOPA as well as PD98059
treatment.
Hspa4, Hcrtr1, Fgfr2, and Cadm2 are also significantly
regulated with L-DOPA and PD98059 treatment. The official
full name of Hspa4 is heat shock protein family A member 4, a
member of the heatshock protein (HSP) family 110 (Banduseela
et al., 2013). Most HSPs act as chaperones and imperfections in
their function can lead to an accumulation of misfolded proteins
(Patterson, 2006). HSPA4 has interaction with PD-causing genes,
including parkin, DJ-1 and PINK1, although the role of HSPA4 in
PD progression and pathogenesis is unclear (van derMerwe et al.,
2015). The official full name of Hcrtr1 is hypocretin receptor 1.
HCRTR1 is one of G-protein coupled receptor, and takes part
in positive regulation of ERK1/2 cascade and cytosolic calcium
ion concentration. The official full name of Fgfr2 is fibroblast
growth factor receptor 2. FGFR2 is an important neurotrophic
factor, and may contribute to the development of mesencephalic
dopaminergic neurons (Baron et al., 2012). The official full
name of Cadm2 is cell adhesion molecule 2. CADM2 plays an
important role for synapse organization, and provides regulated
trans-synaptic adhesion (Tanabe et al., 2013). Clearly, a number
of other genes could be listed, but these gene regulations need
to be investigated in depth to establish their specific relation
to behavioral changes and to gain insights into their functional
roles.
In conclusion, our results reveal the interplay among p-
ERK1/2, 1FosB, p-H3, TH, ARNT in the mechanisms of
LID. Additionally, the series of genes identified in this study
are opening new pathways for further insights into the
molecular changes associated with LID. Most noticeably are the
interrelated regulation of p-ERK1/2-NURR1-TH-ARNT genes
and p-ERK1/2-1FosB-UBASH3B genes. Further studies of these
mechanisms may help identify targets for developing new LID
treatments.
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